These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Primary membranous nephropathy in children and adolescents: a single-centre report from South Asia. Ramachandran R; Nayak S; Kumar V; Kumar A; Agrawal N; Bansal R; Tiewsoh K; Nada R; Rathi M; Kohli HS Pediatr Nephrol; 2021 May; 36(5):1217-1226. PubMed ID: 33108509 [TBL] [Abstract][Full Text] [Related]
3. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach. Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260 [TBL] [Abstract][Full Text] [Related]
4. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up. Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy. Guo Y; Wu X; Liu L; Zhang H; Yang L; Chen W Ren Fail; 2020 Nov; 42(1):122-130. PubMed ID: 31957527 [No Abstract] [Full Text] [Related]
6. [Long-term efficacy of low-dose rituximab treatment in patients with primary membranous nephropathy]. Qi Y; Jia JY; Gu QH; Zheng ZF; Li LN; Li D; Jia ZH; Xue Y; Yan TK Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(40):3201-3206. PubMed ID: 36319174 [No Abstract] [Full Text] [Related]
7. Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy. Netti GS; Infante B; Spadaccino F; Godeas G; Corallo MG; Prisciandaro C; Croce L; Rotondi M; Gesualdo L; Stallone G; Grandaliano G; Ranieri E J Immunol Res; 2019; 2019():8483650. PubMed ID: 31781684 [TBL] [Abstract][Full Text] [Related]
8. Primary membranous nephropathy in adolescence: A prospective study. Kumar V; Varma AK; Nada R; Ghosh R; Suri D; Gupta A; Kumar V; Rathi M; Kohli H; Jha V; Gupta K; Ramachandran R Nephrology (Carlton); 2017 Sep; 22(9):678-683. PubMed ID: 27334445 [TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of Guo Y; Guo N; Wang J; Wang R; Tang L Ren Fail; 2021 Dec; 43(1):729-736. PubMed ID: 33904354 [TBL] [Abstract][Full Text] [Related]
10. Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen. Ragy O; Hamilton P; Pathi A; Ahmed AAM; Mitra S; Kanigicherla DAK Glomerular Dis; 2023; 3(1):88-97. PubMed ID: 37113496 [TBL] [Abstract][Full Text] [Related]
11. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy. Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B Front Immunol; 2021; 12():738788. PubMed ID: 34721403 [TBL] [Abstract][Full Text] [Related]
13. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Barrett C; Willcocks LC; Jones RB; Tarzi RM; Henderson RB; Cai G; Gisbert SI; Belson AS; Savage CO Nephrol Dial Transplant; 2020 Apr; 35(4):599-606. PubMed ID: 31243451 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study. Zhang S; Huang J; Dong J; Li Z; Sun M; Sun Y; Chen B Front Immunol; 2023; 14():1156470. PubMed ID: 37187749 [TBL] [Abstract][Full Text] [Related]
15. [A novel approach to rapid induction of remission in primary membranous nephropathy]. Dobronravov VA; Bystrova OB; Kochoyan ZS; Fomicheva EN Ter Arkh; 2021 Jun; 93(6):706-712. PubMed ID: 36286838 [TBL] [Abstract][Full Text] [Related]
16. [Membranous nephropathy: New insights in therapeutic approach]. Dahan K Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748 [TBL] [Abstract][Full Text] [Related]
17. Clinical Phenotypes and Predictors of Remission in Primary Membranous Nephropathy. Jurubiță R; Obrișcă B; Sorohan B; Achim C; Micu GE; Mircescu G; Ismail G J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34203607 [TBL] [Abstract][Full Text] [Related]
18. Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort. Wang X; Cui Z; Zhang YM; Qu Z; Wang F; Meng LQ; Cheng XY; Liu G; Zhou FD; Zhao MH Nephrol Dial Transplant; 2018 Sep; 33(9):1558-1563. PubMed ID: 29149305 [TBL] [Abstract][Full Text] [Related]
19. Intravenous pulse cyclophosphamide and steroids induce immunological and clinical remission in New-incident and relapsing primary membranous nephropathy. Kanigicherla DAK; Hamilton P; Czapla K; Brenchley PE Nephrology (Carlton); 2018 Jan; 23(1):60-68. PubMed ID: 27778424 [TBL] [Abstract][Full Text] [Related]